Mogamulizumab

Mogamulizumab (Poteligeo, Kyowa Kirin Holdings B.V.) has 1 EU-approved indication in 1 tumour type.
Approved indications of Mogamulizumab
Biomarker requirementRegimenSettingConditions
T-cell lymphoma1
None
Monotherapy
2L
Cutaneous T-cell lymphoma only; After at least one prior systemic therapy
Full text of section 4.1 (therapeutic indications)

POTELIGEO is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.

Label history

10 changes to the Poteligeo label since 2020, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes